JAMA Clinical Reviews

Ticagrelor or Clopidogrel for Antiplatelet Therapy After Percutaneous Intervention for Acute Coronary Syndrome?

10.27.2020 - By JAMA NetworkPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

The Platelet Inhibition and Patient Outcomes (PLATO) trial showed that ticagrelor had better outcomes than clopidogrel for avoiding thrombotic complications following acute coronary syndrome. Subsequent trials suggested that the outcomes for the drugs were about the same. The effects of ticagrelor and clopidogrel were examined in a very large observational study performed by Harlan Krumholz, MD, and colleagues, published in the October 27, 2020, issue of JAMA. Dr Krumholz explains how his study was performed and what it showed. Related Article: Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention ohdsi.org

More episodes from JAMA Clinical Reviews